Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

News

News
FDA Approves Biosimilar for Certain Patients With Breast or Gastric Cancers
06/14/2019
The FDA has approved trastuzumab-anns as a biosimilar to trastuzumab.
The FDA has approved trastuzumab-anns as a biosimilar to trastuzumab.
The FDA has approved...
06/14/2019
Oncology

Advertisement

News
Year in Review: New Oncology Treatments and Expanded Indications Approved in 2018
12/20/2018
The year 2018 reflects the continued growth in new drug approvals by the FDA that has been seen over the past few years. Here we highlight some of the notable approvals of first-in-class drugs, novel drugs for areas otherwise lacking in...
The year 2018 reflects the continued growth in new drug approvals by the FDA that has been seen over the past few years. Here we highlight some of the notable approvals of first-in-class drugs, novel drugs for areas otherwise lacking in...
The year 2018 reflects the...
12/20/2018
Oncology
News
Biosimilar Drugs in Oncology: What Has the FDA Approved So Far?
12/20/2018
Oncology Learning Network provides a brief overview of oncology and oncology supportive biosimilars that have been approved to date.
Oncology Learning Network provides a brief overview of oncology and oncology supportive biosimilars that have been approved to date.
Oncology Learning Network...
12/20/2018
Oncology
News
FDA Approves Biosimilar for Certain Patients With HER2-Overexpressing Breast Cancer
12/18/2018
The FDA has approved a biosimilar to trastuzumab for the treatment of patients with HER2-overexpressing breast cancer.
The FDA has approved a biosimilar to trastuzumab for the treatment of patients with HER2-overexpressing breast cancer.
The FDA has approved a...
12/18/2018
Oncology

Advertisement

News
Rituximab Biosimilar Well-Tolerated, as Effective as Reference Drug in FL
11/14/2018
A biosimilar to rituximab is well-tolerated and just as effective as its reference drug in patients with low-tumor burden FL.
A biosimilar to rituximab is well-tolerated and just as effective as its reference drug in patients with low-tumor burden FL.
A biosimilar to rituximab is...
11/14/2018
Oncology
News
FDA Approves Neulasta Biosimilar for Recipients of Myelosuppressive Chemo
11/02/2018
The FDA approved a biosimilar that can decrease the occurrence of infections, as manifested by febrile neutropenia.
The FDA approved a biosimilar that can decrease the occurrence of infections, as manifested by febrile neutropenia.
The FDA approved a biosimilar...
11/02/2018
Oncology
News
FDA Approves Biosimilar to Treat Adverse Chemotherapy Effects
07/23/2018
The FDA has granted approval to a biosimilar of a common drug used for the treatment of patients experiencing chemotherapy-related neutropenia.
The FDA has granted approval to a biosimilar of a common drug used for the treatment of patients experiencing chemotherapy-related neutropenia.
The FDA has granted approval to...
07/23/2018
Oncology

Advertisement

News
FDA Approves Mylan Drug as First Biosimilar to Amgen's Neulasta
06/05/2018
Mylan NV on Monday beat a clutch of drugmakers racing to get a biosimilar to Amgen Inc's blockbuster drug, Neulasta, to market.
Mylan NV on Monday beat a clutch of drugmakers racing to get a biosimilar to Amgen Inc's blockbuster drug, Neulasta, to market.
Mylan NV on Monday beat a clutch...
06/05/2018
Oncology

Advertisement

Advertisement

Advertisement

Recent News

News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use